

D 4
33. (Amended) A pharmaceutical composition for
detecting pancreatitis which comprises the antibody according
to claim 20.

REMARKS


The above amendments to the claims are made to place
the claims in better form for examination under U.S. practice.

Applicants respectfully await the results of a first
examination on the merits.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Sheridan Neimark
Registration No. 20,520

SN:jec
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,A\Aoyb\Uemura 5\PTO\preliminaryamd30July01.doc

"Version with Markings to Show Changes Made"

11. (Amended) A vector comprising the nucleotide sequence according to ~~any one of claims 2, 4, 6 and 8-10~~ claim 36.

12. (Amended) Transformed cells having the nucleotide sequence according to ~~any one of claims 2, 4, 6 and 8-10 in an expressible state~~ claim 36.

13. (Amended) A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence (aa), (bb), (cc), (mm) or (nn) of claim 36 according to either of claims 2 and 9, and collecting hBSSP5 produced.

14. (Amended) A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence (dd), (ee), (ff), (gg), (hh), (ii), (jj), (kk), (ll), (oo) or (pp) of claim 36 according to any one of claims 4, 6, 8 and 10, and collecting mBSSP5 produced.

15. (Amended) The process according to claim 13 or 14, wherein the cells are *E. coli* cells, animal cells or insect cells.

20. (Amended) An antibody against the protein according to any one of claims 1, 3, 5 and 7 claim 35 or a fragment thereof.

22. (Amended) A process for producing a monoclonal antibody against the protein according to ~~any one of claims 1, 3, 5 and 7~~ claim 35 or a fragment thereof which comprises administering the protein according to ~~any one of claims 1, 3, 5 and 7~~ claim 35 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

23. (Amended) A method for determining the protein according to ~~any one of claims 1, 3, 5 and 7~~ claim 35 or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

24. (Amended) A method for determining hBSSP5 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein (a) or (b) of claim 35 according to claim 1] or a modified derivative thereof or a fragment thereof and a labeled antibody with hBSSP5 or a fragment thereof in the specimen to detect a sandwich complex produced.

25. (Amended) A method for determining hBSSP5 or a fragment thereof in a specimen which comprises reacting a

monoclonal antibody or a polyclonal antibody against the protein (a) or (b) of claim 35 ~~according to claim 1 or a modified derivative thereof or a fragment thereof with labeled hBSSP5 and hBSSP5 or a fragment thereof in the specimen competitively to detect an amount of hBSSP5 or a fragment thereof in the specimen based on an amount of the labeled hBSSP5 reacted with the antibody.~~

26. The method according to ~~any one of claims 23-25~~ claim 23, wherein the specimen is a body fluid.

27. (Amended) A diagnostic marker for diseases in tissues comprising the protein according to ~~any one of claims 1, 3, 5 and 7~~ claim 35.

32. (Amended) A method for detecting pancreatitis which comprises measuring concentration of the protein according to claim 35 ~~any one of claims 1, 3, 5 and 7~~ in blood or urine.

33. (Amended) A pharmaceutical composition for detecting pancreatitis which comprises the antibody according to claim 20~~-or-21~~.